Substance Use Scientific Working Group

药物使用科学工作组

基本信息

  • 批准号:
    10397173
  • 负责人:
  • 金额:
    $ 19.67万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-04-23 至 2026-03-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY - SUBSTANCE USE SCIENTIFIC WORKING GROUP The Texas Developmental Center for AIDS Research (D-CFAR) is based at Baylor College of Medicine (Baylor) and University of Texas Health Science Center at Houston (UTHealth) and the Texas Biomedical Research Institute (TxBiomed) in San Antonio. It will establish a Substance Use Scientific Working Group (SU- SWG). Substance use trends in the state of Texas are similar to the nation as a whole in showing an increase in opioid use and related emergency department visits and overdose deaths in recent years. Equally concerning are recent trends in the use of methamphetamine, marijuana, cocaine, and alcohol. Substance use and HIV are inextricably linked. Substance use is a well-established risk factor for transmission of the virus. For people living with HIV, substance use and addiction can hasten the progression of HIV and its consequences. Despite its significant impact on HIV, the intersection of substance use and HIV has been an underdeveloped research area, especially in areas of the US with weaker substance use treatment infrastructures like Texas. The proposed Texas D-CFAR SU-SWG will foster a robust research program in three areas that align with the proposed D-CFAR to fill this gap: 1) substance use as a co-factor for transmission of HIV; 2) impact of substance use on progression of HIV and its consequences; 3) novel treatment approaches for HIV prevention and treatment for individuals who use substances. The SU-SWG will support research in these areas by developing key resources, services, pilot funding opportunities, and by fostering discussions and collaborations between Texas D-CFAR members. To achieve its goals, the SU-SWG will: 1) Work with the proposed Cores and Core services to develop and support substance use as a critical area of research focus for ending HIV and optimizing HIV health in Texas. 2) Inform the Texas D-CFAR community about ongoing and future research on the intersection of substance use and HIV, both at our D-CFAR, nationally, and internationally. 3) Inform the D-CFAR community about external funding opportunities on substance use, provide pilot project funding opportunities through the Developmental Core, and catalyze collaborations. 4) Expand the SU-SWG by opening membership to substance use and HIV researchers and trainees at other Texas institutions. To achieve these aims, the D-CFAR has assembled a group of established and early stage investigators in both HIV and substance use to bring together in the SU-SWG to foster research in the intersection of these two epidemics. The SU-SWG includes persons with deep connections to the community and local public health officials as well as academicians who have developed and lead innovative programs to deliver substance use treatments. The SU-SWG leadership, in collaboration with the D-CFAR leadership, has identified a comprehensive 5-year action plan, set of activities, policies and procedures and evaluation metrics to ensure success. This activity organized by the SU-SWG will accelerate efforts to end HIV and improve the health of people with HIV in Texas and beyond.
项目摘要-物质使用科学工作组

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JOY Marie SCHMITZ其他文献

JOY Marie SCHMITZ的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JOY Marie SCHMITZ', 18)}}的其他基金

Substance Use Scientific Working Group
药物使用科学工作组
  • 批准号:
    10609486
  • 财政年份:
    2021
  • 资助金额:
    $ 19.67万
  • 项目类别:
Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention
制定可卡因戒断和预防复发的适应性干预措施
  • 批准号:
    9028634
  • 财政年份:
    2016
  • 资助金额:
    $ 19.67万
  • 项目类别:
Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention
制定可卡因戒断和预防复发的适应性干预措施
  • 批准号:
    9334822
  • 财政年份:
    2016
  • 资助金额:
    $ 19.67万
  • 项目类别:
Clinical Trial of Dopamine-Serotonin Medication Combination in Cocaine Dependence
多巴胺-血清素药物组合治疗可卡因依赖的临床试验
  • 批准号:
    8004213
  • 财政年份:
    2010
  • 资助金额:
    $ 19.67万
  • 项目类别:
Adaptive Clinical Trial of Adenosine A2a Antagonist in Cocaine Dependence
腺苷 A2a 拮抗剂治疗可卡因依赖的适应性临床试验
  • 批准号:
    8004209
  • 财政年份:
    2010
  • 资助金额:
    $ 19.67万
  • 项目类别:
SCREENING MEDICATIONS FOR COCAINE CESSATION & RELAPSE PREVENTION
筛查戒除可卡因的药物
  • 批准号:
    7626824
  • 财政年份:
    2008
  • 资助金额:
    $ 19.67万
  • 项目类别:
PHARMACOTHERAPY DOSING REGIMEN
药物治疗剂量方案
  • 批准号:
    7626825
  • 财政年份:
    2008
  • 资助金额:
    $ 19.67万
  • 项目类别:
Contingency Management plus Levodopa/Carbidopa for Trtment. of Cocaine Dependence
应急管理加左旋多巴/卡比多巴进行治疗。
  • 批准号:
    7492936
  • 财政年份:
    2007
  • 资助金额:
    $ 19.67万
  • 项目类别:
Contingency Management plus Levodopa/Carbidopa for Trtment. of Cocaine Dependence
应急管理加左旋多巴/卡比多巴进行治疗。
  • 批准号:
    7622158
  • 财政年份:
    2007
  • 资助金额:
    $ 19.67万
  • 项目类别:
Contingency Management plus Levodopa/Carbidopa for Trtment. of Cocaine Dependence
应急管理加左旋多巴/卡比多巴进行治疗。
  • 批准号:
    7808894
  • 财政年份:
    2007
  • 资助金额:
    $ 19.67万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 19.67万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 19.67万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 19.67万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 19.67万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 19.67万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 19.67万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 19.67万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 19.67万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 19.67万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 19.67万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了